… our institutional lung cancer database for tumors with EGFR kinase domain mutations that
were also … profiling, and evaluated tumor response to EGFR tyrosine kinase inhibitors (TKIs). …

… in EGFR mutation status are yet to be fully elucidated. The aim of this systematic review is to
describe the EGFR mutation … map of EGFR mutation prevalence (a ‘global EGFR mutMap’). …

… In this study, we searched for EGFR mutations in a large cohort … and pathologic features
including KRAS or TP53 mutations. … lung cancer carried mutations in the TK domain of the EGFR …

… TKIs, we rebiopsied recurrent disease sites in patients with EGFR mutations who developed
resistance to EGFR TKIs. Molecular analyses were performed to assess the prevalence of …

… We randomly assigned 230 patients with metastatic, non–small-cell lung cancer and EGFR
mutations who had not previously received chemotherapy to receive gefitinib or carboplatin–…

… was 10 months compared to 2 months for EGFR mutation negative patients… EGFR mutation
patients and 13 months for mutation negative patients. This study emphasizes EGFR mutation …

… The results of this study suggest that EGFR mutant subtypes of non-small-cell lung cancer
have distinct response to immune checkpoint inhibitors and distinct tumor mutation burdens. …

… EGFR-mediated downstream signaling activation. In lung cancer cells with EGFR mutations,
… of the intracellular domain of EGFR and significantly attenuate the autophosphorylation of …

… EGFR mutations now guide the clinical use of EGFR-targeted therapy in lung cancer.
However, standard EGFR mutation analysis requires a minimum amount of tumor tissue, which …

… To examine the role of EGFR TK domain mutations in lung cancer pathogenesis, we searched
for EGFR TK domain mutations in genomic DNA isolated from primary lung tumors from …